The Nevada Senate voted 18 to 2 today to approve Senate Joint Resolution 10, a measure urging Congress to reschedule certain psychedelic compounds and expand research into their therapeutic use for treating mental health conditions.
Mescaline (top left), ibogaine (top right), psilocybin mushrooms (bottom left), and DMT (bottom right).
The resolution, backed by a broad coalition of 27 senators and assemblymembers, highlights growing evidence that substances such as psilocybin, MDMA, DMT, ibogaine, mescaline and others could be effective in treating serious conditions like PTSD, treatment-resistant depression, anxiety, substance use disorders and chronic pain.
Citing data from numerous clinical trials and studies at major research institutions including Johns Hopkins, Stanford and Yale, the resolution points to FDA designations of certain psychedelic therapies as “Breakthrough Therapies” and emphasizes their favorable safety profiles when administered in clinical settings.
SJR 10 calls on Congress and federal agencies to increase research funding, streamline research approvals, and reschedule these compounds to a classification that better reflects their medical value and low abuse potential. It also urges the federal government to establish legal protections for individuals and entities operating under state psychedelic laws, and to expand compassionate use access under the federal Right to Try Act.
The resolution underscores Nevada’s commitment to addressing mental health challenges through innovative science and treatment options and supports further psychedelic research at institutions within the state. The measure now moves to the Assembly for consideration.
